DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of Vanda Pharmaceuticals Inc. of Upcoming Deadline
13 8월 2013 - 7:53AM
Business Wire
Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of
Vanda Pharmaceuticals Inc. (NASDAQ GM:
VNDA)?
- Did you purchase your shares before
December 18, 2012, or between December 18, 2012 and June 18,
2013?
- Did you lose money in your
investment in Vanda Pharmaceuticals Inc.?
- Do you want to discuss your
rights?
Rigrodsky & Long, P.A., including former Special Assistant
United States Attorney, Timothy J. MacFall, reminds shareholders of
Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ GM:
VNDA) of an upcoming deadline involving a securities fraud class
action lawsuit commenced against the Company.
A complaint was filed in the United States District Court for
the District of Columbia on behalf of all persons or entities that
purchased the common stock of Vanda between December 18, 2012 and
June 18, 2013, inclusive (the “Class Period”), alleging violations
of the Securities Exchange Act of 1934 against the Company and
certain of its officers (the “Complaint”). If you wish to serve as
lead plaintiff, you must move the Court no later than August 26,
2013.
If you purchased shares of Vanda during the Class Period, or
purchased shares prior to the Class Period and still hold Vanda,
and wish to discuss this action or have any questions concerning
this notice or your rights or interests, please contact Timothy J.
MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A.,
825 East Gate Boulevard, Suite 300, Garden City, NY at (888)
969-4242, by e-mail to info@rigrodskylong.com, or at:
http://www.rigrodskylong.com/investigations/vanda-pharmaceuticals-inc-vnda.
A lead plaintiff is a representative party acting on behalf of
other class members in directing the litigation. In order to be
appointed lead plaintiff, the Court must determine that the class
member’s claim is typical of the claims of other class members, and
that the class member will adequately represent the class. Your
ability to share in any recovery is not, however, affected by the
decision whether or not to serve as a lead plaintiff. Any member of
the proposed class may move the court to serve as lead plaintiff
through counsel of their choice, or may choose to do nothing and
remain an absent class member.
While Rigrodsky & Long, P.A. did not file the Complaint in
this matter, the firm, with offices in Wilmington, Delaware and
Garden City, New York, regularly litigates securities class,
derivative and direct actions, shareholder rights litigation and
corporate governance litigation, including claims for breach of
fiduciary duty and proxy violations in the Delaware Court of
Chancery and in state and federal courts throughout the United
States.
Attorney advertising. Prior results do not guarantee a similar
outcome.
Rigrodsky & Long, P.A.Timothy J. MacFall, EsquirePeter
Allocco888-969-4242516-683-3516Fax:
302-654-7530info@rigrodskylong.comhttp://www.rigrodskylong.com
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024